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OBJECTIVE—Extracellular nucleotides are important mediators
of inﬂammatory responses and could also impact metabolic ho-
meostasis. Type 2 purinergic (P2) receptors bind extracellular
nucleotides and are expressed by major peripheral tissues respon-
sible for glucose homeostasis. CD39/ENTPD1 is the dominant
vascular and immune cell ectoenzyme that hydrolyzes extracellular
nucleotides to regulate purinergic signaling.
RESEARCH DESIGN AND METHODS—We have studied
Cd39/Entpd1-null mice to determine whether any associated
changes in extracellular nucleotide concentrations inﬂuence glu-
cose homeostasis.
RESULTS—Cd39/Entpd1-null mice have impaired glucose toler-
ance and decreased insulin sensitivity with signiﬁcantly higher
plasma insulin levels. Hyperinsulinemic-euglycemic clamp studies
indicate altered hepatic glucose metabolism. These effects are
mimicked in vivo by injection into wild-type mice of either exoge-
nous ATP or an ecto-ATPase inhibitor, ARL-67156, and by exposure
of hepatocytes to extracellular nucleotides in vitro. Increased serum
interleukin-1, interleukin-6, interferon-, and tumor necrosis fac-
tor- levels are observed in Cd39/Entpd1-null mice in keeping with
a proinﬂammatory phenotype. Impaired insulin sensitivity is accom-
paniedbyincreasedactivationofhepaticc-JunNH2-terminalkinase/
stress-activated protein kinase in Cd39/Entpd1 mice after injection
of ATP in vivo. This results in decreased tyrosine phosphorylation
of insulin receptor substrate-2 with impeded insulin signaling.
CONCLUSIONS—CD39/Entpd1 is a modulator of extracellular
nucleotide signaling and also inﬂuences metabolism. Deletion of
Cd39/Entpd1 both directly and indirectly impacts insulin regulation
and hepatic glucose metabolism. Extracellular nucleotides serve as
“metabolokines,” indicating further links between inﬂammation and
associated metabolic derangements. Diabetes 57:2311–2320,
2008
P
urinergic signaling elements comprise a ubiqui-
tous sensing network within the extracellular
environment. In this system, extracellular nucle-
otides, such as ATP, ADP, and UTP, and extra-
cellular nucleosides, such as adenosine, trigger differential
cellular responses (1,2). Purinergic signaling pathways
require extracellular nucleotide release mechanisms, puri-
nergic receptors for these mediators (type 2 purinergic
[P2] receptors), and regulated expression of ectonucleo-
tidases that hydrolyze extracellular nucleotides to gener-
ate adenosine (3–5). Extracellular nucleotides are
provided by the secretion/release of intracellular sub-
strates, and levels are increased in hypoxia, injury, me-
chanical stress, and inﬂammation.
Several reports suggest roles for extracellular nucleo-
tides and nucleosides in glucose homeostasis (e.g., stimu-
lation of insulin secretion from islets [6–8], modulation of
glucose uptake [9,10]). P2 receptors are expressed by
insulin-sensitive tissues and also by immune cells. Extra-
cellular nucleotides activate inﬂammatory pathways, in-
ducing expression of proinﬂammatory cytokines including
interleukin-1 (11), interferon- (12), and activating inﬂam-
matory kinase such as c-Jun NH2-terminal kinase (c-JNK)
through the activation of P2 receptors (13,14). Protein
kinase C can be also activated by these pathways (15).
These kinases phosphorylate serine residues of insulin
receptor substrate (IRS)-1/2, resulting in impaired insulin
signaling by precluding tyrosine phosphorylation required
to recruit phosphoinositide 3-kinase (16,17).
CD39/ENTPD1 is an ectoenzyme that hydrolyzes extracel-
lular nucleotides and is predominantly expressed in vascular
endothelial cells and immune cells. We have previously
shown that deletion of Cd39/Entpd1 results in disordered
purinergic signaling responses that compromise vascular
thromboregulation and augment inﬂammatory responses
(3,5,12). Here, we show that Cd39/Entpd1-null mice dem-
onstrate impaired glucose tolerance secondary, at least in
part, to hepatic insulin resistance. This phenomenon is
associated with increased levels of hepatocyte c-JNK
activation in response to extracellular nucleotides, result-
ing in aberrant IRS-2 phosphorylation within the livers of
the mutant mice. Our studies clearly establish links be-
tween extracellular nucleotide–mediated regulation of glu-
cose metabolism and inﬂammation that are uniquely
inﬂuenced by the vascular expression of Cd39/Entpd1.
RESEARCH DESIGN AND METHODS
Cd39/Entpd1-null mice have been described in detail elsewhere (3) and were
backcrossed six times onto the C57BL/6 genetic background. C57BL/6 wild-
type mice were obtained from Taconic. Male mice were used in all experi-
ments. Mice were housed under conditions of controlled temperature and
illumination (12-h light cycle, lights on at 0700 h). Unless otherwise stated,
mice were fed a normal diet ad libitum. All research and animal care protocols
were approved by the Beth Israel Deaconess Medical Center Animal Experi-
mentation Ethics Committee.
Glucose tolerance and insulin tolerance tests. A glucose tolerance test
(GTT) was carried out with overnight-fasted (16 h) mice at 9 and 16 weeks old.
GTT was performed by intraperitoneal injection of glucose (1 g D-glucose/kg
body wt). An insulin tolerance test (ITT) was performed by intraperitoneal
injection of human regular insulin (0.75 units insulin/kg body wt; Eli Lilly) at
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DIABETES, VOL. 57, SEPTEMBER 2008 23112 h after removal of food. Blood glucose levels were determined with the
OneTouch Ultra blood glucose–monitoring system (LifeScan). To determine
effects of exogenous nucleotides on GTT, 7-week-old wild-type mice were
fasted overnight. After basal plasma glucose was measured, the experimental
mice were injected with ATP, ADP, UTP, or UDP solution (0.5 mmol/kg body
wt) intraperitoneally, whereas control animals were administered saline. At 30
min, each animal was subjected to a GTT (n  5–6 per group). The effects of
an ecto-ATPase inhibitor, ARL-67156 (5 mg/kg body wt), on the GTT were
examined in a similar manner.
Hyperinsulinemic-euglycemic clamp study. Hyperinsulinemic-euglycemic
clamp studies were performed on 16- to 17-week-old mice. Four days before
experiments, an indwelling catheter was inserted in the right internal jugular
vein of experimental animals. After an overnight fast, a 120-min hyperinsu-
linemic-euglycemic clamp was conducted in awake mice, as previously
described (18). Infusions of human insulin (Eli Lilly) at a rate of 15 pmol  kg
1 
min
1 raised plasma insulin levels to 900 pmol/l (wild type: 863.0  151.4
pmol/l [n  8], knockout: 890.3  108.4 pmol/l [n  8]; P  0.8741), and 40%
glucose was infused at variable rates to clamp the plasma glucose levels at
6.5 mmol/l using microdialysis pumps. At the end of the clamp studies, each
tissue was harvested and frozen in liquid nitrogen. Clamp results were
analyzed as described previously (18).
Measurements of metabolites, serum hormones, and cytokines. Insulin
concentrations were determined using a rat insulin enzyme-linked immu-
nosorbent assay (ELISA) kit with mouse insulin standards (Crystal Chem).
Serum triglyceride and free fatty acid concentrations were measured using a
colorimetric kit (Sigma-Aldrich) and a NEFA-C kit (Wako Chem), respectively.
Serum 3-hydroxybutyric acid levels were determined using a colorimetric
assay kit (Wako Chem). Plasma leptin was measured using a mouse leptin
ELISA kit (Crystal Chem) and a mouse adiponectin radioimmunoassay kit
(Linco Research). Urine catecholamine levels were determined by an ELISA
kit (Alpco Diagnostics). Serum cytokine levels (interleukin-1, interleukin-6,
interferon-, and tumor necrosis factor-) were measured by ELISA (eBio-
sciences).
Measurements of nuclear factor-B p65. Liver nuclear extracts were
prepared with the Nuclear Extract Kit (Active Motif), according to the
manufacturer’s instruction. Nuclear factor-B (NFB) p65 levels in equal
amounts of nuclear extracts were determined with TransAM NFBp65 (Active
Motif).
Body composition. A PIXIMUS Densitometer (LUNAR) was used for the
measurement of body composition in anesthetized mice (19).
Indirect calorimetry and daily activity. In vivo indirect calorimetry was
performed in metabolic chambers using an Oxymax system (Columbus
Instruments) in mice at 16–17 weeks old. To calculate oxygen consumption
(VO2), carbon dioxide production (VCO2), and RQ (ratio of VCO2 to VO2), gas
concentrations were monitored at the inlet and outlet of the sealed chambers.
Global daily activity was monitored by counting the number of times that an
individual mouse blocked an infrared beam running along x- and y-axes inside
an individual cage.
Isolation and culture of hepatocytes. Hepatocytes were isolated from
7-week-old mice according to the method of Harman et al. (20). Hepatocytes
were further puriﬁed by centrifugation with Percoll and plated onto gelatin-
coated dishes. Unattached cells were removed at 6 h. The cells were used for
experiments at 24-h postisolation.
Glucose uptake by cultured hepatocytes. Primary murine hepatocytes
were plated onto six-well plates at 4 	 10
5 cells/well. The cells were cultured
in a 37°C CO2 incubator in William’s E buffer with 10% FCS. Subsequently,
cells were serum starved overnight in William’s E buffer with 0.1% BSA. The
cells were washed twice with Krebs-Ringer/Pi/Hepes (KRPH) and treated with
either 100 nmol/l insulin or KRPH buffer (control) for 30 min at 37°C, followed
by addition of 10 mmol/l 2-deoxy-D-glucose (2-DG) containing 0.3 mCi/ml
2-deoxy-D-[
3H]glucose. After a 10-min incubation, the cells were washed with
ice-cold PBS three times, air dried, then lysed with ice-cold 0.2 N NaOH.
Radioactivity was determined by scintillation counting, and protein concen-
trations were determined using the Bio-Rad DC protein assay. 2-DG uptake
was expressed as cpm  mg
1  ml
1 of protein concentration. Similar protocol
was used to measure 2-deoxy-D-[
3H]glucose uptake in wild-type cells that were
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FIG. 1. Cd39/Entpd1
/ mice exhibit impaired glucose tolerance and insulin resistance. A: GTT. B: Plasma insulin levels during GTT. C: ITT. Œ,
Cd39/Entpd1
/ mice; , wild-type mice (9 weeks old, n  6). D–F: Effects of different nucleotides on GTT in wild-type mice (n  5–6). D: ,
ATP-treated mice; Œ, UTP-treated mice; f, saline control. E: , ADP-treated mice; Œ, UDP-treated mice; f, saline control. F: ‚, ARL-67156–
treated mice; f, saline control. Data are means  SE. **P < 0.05; *P < 0.1.
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mol/l ATP or KRPH buffer for 30 min before
commencing the insulin-stimulated 2-DG uptake assay.
Measurement of gluconeogenesis in cultured hepatocytes. Primary
hepatocytes were serum starved overnight in DMEM with 0.4% FCS and 5
mmol/l D-glucose, washed three times with KRPH buffer, and incubated with
KRPH buffer containing 20 mmol/l lactate and 2 mmol/l pyruvate (basal) or
KRPH buffer containing either 10 nmol/l insulin or 100 nmol/l insulin with 20
mmol/l lactate and 2 mmol/l pyruvate. Glucose content in each aliquot was
measured using an Amplex Red Glucose Assay (Invitrogen). Glucose produc-
tion was expressed as measured ﬂuorescence  mg
1  ml
1 of protein
concentration. Similar experimental protocol was used to measure glucose
production in wild-type cells that were either pretreated with 100 
mol/l ATP
or KRPH buffer for 30 min before commencing the insulin-stimulated gluconeo-
genesis assay.
Western blotting. Tissue or cell lysates were prepared in the lysis buffer as
described previously (18). Clariﬁed supernatant was separated on SDS-PAGE
under reducing condition and then transferred to polyvinylidene ﬂuoride
membrane for Western blot analysis. For IRS-1 and -2 studies, 500 
go f
cleared lysate was incubated with anti–IRS-1 or anti–IRS-2 antibodies (Up-
state) then captured with protein-A/G Sepharose beads (Sigma-Aldrich). After
washing the beads, IRS-1 or -2 was eluted in SDS-loading buffer and subjected
to Western blot analysis with anti–phosphotyrosine antibody or anti–IRS-1 or
anti–IRS-2 antibodies. Images were taken on a Kodak chemiluminescent
image station 2000MM and quantiﬁed with an accompanying software pro-
gram (Kodak). Detection of either phospho-JNK or JNK was carried out using
anti–p-JNK antibody or anti-JNK antibody (Cell Signaling Technolgies). Phos-
pho-Ser731–IRS-2 was detected using speciﬁc antibodies purchased from
Abcam.
Administration of ATP into portal vein. Twelve-week-old male mice were
anesthetized with nembutal then 10 mmol/l ATP, and PBS was administered
via a portal vein at 1.4 
l/g and at 2.5 s/g body wt using a microinfusion pump.
At 30 min of infusion, mice were killed by exsanguination, and immediately
the perfused liver was snap frozen in liquid nitrogen.
Immunohistochemistry. Animals were anesthetized with avertin and killed
by exsanguination. Pancreatic, hepatic, and skeletal muscle tissues were
immediately embedded in OCT compound in an isopentene–liquid nitrogen
TABLE 1
Comparison of blood analysis data of Cd39/Entpd1
/
Wild type Cd39/Entpd1
/ P
Body weight (g)
9 weeks (fasting) 24.6  0.3 25.3  0.9 0.426
9 weeks (fed) 26.6  0.4 27.3  0.9 0.418
16 weeks (fasting) 27.2  0.3 29.1  1.1 0.11
16 weeks (fed) 30.2  0.4 31.6  1.0 0.24
Fasting glucose (mg/dl)
9 weeks 95  59 7  6 0.426
16 weeks 105  3 104  2 0.331
Fed glucose (mg/dl)
9 weeks 185  8 190  6 0.418
16 weeks 189  3.7 202  8.1 0.09
Fasting insulin (pg/ml)
9 weeks 0.34  0.07 0.38  0.13 0.791
16 weeks 0.39  0.12 0.79  0.18 0.028
Fed insulin (pg/ml)
9 weeks 1.51  0.07 2.02  0.22 0.0366
16 weeks 0.74  0.05 1.74  0.24 0.005
Fasting triglycerides (mg/dl)
9 weeks 35  94 7  4 0.252
15 weeks 60  46 5  5 0.225
35 weeks 45  49 5  15 0.01
Fed triglycerides (mg/dl)
9 weeks 57  65 7  4 0.976
16 weeks 40  55 4  5 0.067
Fasting free fatty acids (mmol/l)
9 weeks 1.08  0.07 0.98  0.04 0.261
15 weeks 1.21  0.05 1.17  0.03 0.492
35 weeks 0.71  0.04 1.01  0.11 0.013
Fed free fatty acids (mmol/l)
9 weeks 0.49  0.02 0.53  0.02 0.135
16 weeks 2.94  0.08 3.14  0.13 0.212
Fasting 3-hydroxybutyrate (mmol/l)
15 weeks 1.58  0.05 1.64  0.05 0.453
Leptin (ng/ml)
16 weeks 12.1  0.8 18.6  2.8 0.036
Adiponectin (
g/ml)
16 weeks 9.1  0.6 8.7  0.4 0.623
Visceral fat (% of body wt)
16 weeks 25.3  0.7 27.2  1.9 0.352
Total fat (%)
16 weeks 24.6  0.5 27.0  1.9 0.131
Serum cytokines (15 weeks, fasting)
Interleukin-1 (pg/ml) 1.16  0.88 8.05  3.43 0.049
Interferon- (pg/ml) 41.5  6.2 80.6  10.5 0.01
Interleukin-6 (Pg/ml) 1.71  0.75 5.14  1.61 0.037
Tumor necrosis factor- (arbitrary units) N.D (below range) 1.53  0.45 0.05
Data are mean  SE from 6–10 animals of each group.
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DIABETES, VOL. 57, SEPTEMBER 2008 2313freezing bath. Brown adipose tissue (BAT) was ﬁxed in zinc ﬁxative solution
(BD Biosciences) for 1.5 days. The tissue sections were used for immunohis-
tochemical staining with antibodies against Cd39/Entpd1 (3), Cd31 (BD
Biosciences), insulin, and glucagon (Dako).
Real-time PCR for gluconeogenetic enzymes. Liver total RNA was puriﬁed
with a Qiagen RNAeasy mini-kit and used to synthesis cDNA using an
Invitrogen ﬁrst-strand cDNA synthesis kit. Real-time PCR was performed with
a iTaq SYBR Green Supermix with ROX (Bio-Rad) on a Stratagene MX3000P
quantitative PCR system. The primers used were TGGTAGCCCTGTCTTTC
TTTG and TTCCAGCATTCACACTTTCCT for glucose-6-phosphatase and
ACACACACACATGCTCACAC and ATCACCGCATAGTCTCTGAA for phos-
phoenolpyruvate carboxylase (21). Actin values were used for normalization.
RESULTS
Cd39/Entpd1 deletion results in abnormalities in GTTs
and ITTs. Cd39/Entpd1 knockout (Cd39/Entpd1
/) mice
were subjected to GTTs and ITTs at 9 weeks of age (Fig.
1). Blood glucose levels were signiﬁcantly higher in Cd39/
Entpd1
/ mice throughout the GTT when compared with
wild-type mice (Fig. 1A). Plasma insulin levels during the
GTT were also consistently higher in Cd39/Entpd1
/
mice when compared with wild-type mice, suggesting
insulin resistance in Cd39/Entpd1
/ mice (Fig. 1B). Cd39/
Entpd1
/ mice also exhibited impaired responses to
insulin during the ITT (Fig. 1C). Cd39/Entpd1
/ mice at
16 weeks likewise exhibited glucose intolerance and insu-
lin resistance as determined by a GTT and ITT. There were
no differences in fasting- and fed-state blood glucose levels
between Cd39/Entpd1
/ and wild-type mice.
We then examined effects of exogenous nucleotide
administration upon a GTT in wild-type mice. Increases in
blood glucose levels were observed at 30 min after admin-
istration of ATP versus saline (Fig. 1D). These plasma
glucose increments were sustained in the group treated
with ATP during the GTT. The preadministration of other
nucleotides, UTP, ADP, and UDP, did not substantially
affect glucose tolerance in wild-type mice (Fig. 1D and E).
Preadministration of ARL-67156, a competitive ecto-ATPase
inhibitor, resulted in increases in glucose levels basally and
following a GTT in wild-type mice (Fig. 1F).
Metabolic parameters. Insulin resistance is often ac-
companied by obesity and disordered lipid metabolism.
We therefore assessed other parameters relevant to these
disorders of metabolism (Table 1). Cd39/Entpd1
/ mice
are clearly not obese. Plasma insulin levels were signiﬁ-
cantly higher in fed Cd39/Entpd1
/ mice at all ages tested
and in fasting Cd39/Entpd1
/ mice at 16 weeks of age.
Plasma free fatty acid and triglyceride levels in Cd39/
Entpd1
/ mice were not generally different from wild-
type mice but became statistically higher at 35 weeks of
age. Plasma leptin levels of Cd39/Entpd1
/ mice were
signiﬁcantly higher than in wild-type mice, but adiponectin
levels were comparable. Plasma 3-hydroxybutyrate levels
were comparable in Cd39/Entpd1
/ mice and wild-type
mice.
We also examined sympathetic reactivity in Cd39/
Entpd1e
/ mice. Total adrenaline and noradrenaline lev-
els in urine were not statistically different between these
two groups (adrenaline: Cd39/Entpd1
/ mice 1.49  0.50
pg/day vs. wild-type mice 1.64  0.48 pg/day, P  0.83;
noradrenoline: Cd39/Entpd1
/ mice 2.76  0.90 pg/day
vs. wild-type mice 3.06  0.73 pg/day, P  0.79).
Energy expenditure and activity. We examined the
impact of Cd39/Entpd1 deletion on energy metabolism
(Fig. 2). Heat generation (Fig. 2A), oxygen consumption
(Fig. 2B), and respiratory ratio ((Fig. 2C) were signiﬁ-
cantly lower in Cd39/Entpd1
/ mice, both during dark
and light periods. However, food intake and daily activities
of Cd39/Entpd1
/ mice were comparable with those of
wild-type mice (Fig. 2D).
Hyperinsulinemic-euglycemic clamp studies. To ana-
lyze systemic glucose uptake and usage, we performed
hyperinsulinemic-euglycemic clamp studies. Glucose uptake
in the extrahepatic tissues was not statistically different
between Cd39/Entpd1
/ and wild-type mice (Fig. 3A). Glu-
cose infusion rates during the glucose clamp were, however,
signiﬁcantly lower in Cd39/Entpd1
/ mice (Fig. 3B). Coin-
cidently, glucose disappearance rates (Rd) were lower in
Cd39/Entpd1
/ mice (Fig. 3C). Basal hepatic glucose pro-
duction was normal, but the extent of insulin-dependent
suppression of hepatic glucose production was signiﬁcantly
decreased in Cd39/Entpd1
/ mice (Cd39/Entpd1
/ mice:
26.6  14.4% vs. wild-type mice: 69.5  9.6%; P  0.021) (Fig.
3D). These results suggest that systemic insulin resistance
and glucose intolerance of Cd39/Entpd1
/ mice were asso-
ciated with impaired hepatic responses to insulin and de-
creased Rd.
Phosphoenolpyruvate carboxylase and glucose-6-phospha-
tase expression by RT-PCR were signiﬁcantly higher in
fasting Cd39/Entpd1
/ mice liver than in wild-type mice
liver (phosphoenolpyruvate carboxylase: Cd39/Entpd1
/
mice 128.8  10.2% vs. wild-type mice 100.0  0.6%, P 
0.027; glucose-6-phosphatase: Cd39/Entpd1
/ mice 240.6 
26.1% vs. wild-type mice 100.0  7.3%, P  0.001).
Localization of Cd39/Entpd1 in mouse liver, pan-
creas, BAT, and skeletal muscle. High levels of Cd39/
Entpd1 staining were observed in the endothelium with
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FIG. 2. Calorimetric and functional analyses of Cd39/Entpd1
/ mice.
Cd39/Entpd1
/ mice showed decreased energy expenditure. Food
uptake did not differ between Cd39/Entpd1
/ and wild-type mice. A:
Oxygen consumption. B: Heat generation. C: Respiratory ratio. D:
Accumulated food intake over 3 days (n  6 for wild-type -WT] mice
and n  7 for Cd39/Entpd1
/ mice). Results were analyzed using data
from 3 consecutive days. Data are means  SE. **P < 0.05.
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muscularized blood vessels within liver and skeletal
muscle. Hepatic sinusoidal endothelial cells do not ex-
press Cd39/Entpd1 under basal conditions; however,
Cd39/Entpd1 is expressed by certain hepatic sinusoidal
cells (e.g., Kupffer cells and natural killer T-cells) (22,23).
Hepatocytes and skeletal muscle cells were negative for
Cd39/Entpd1 (Fig. 4A and B). In brown adipose tissue,
Cd39/Entpd1 expression was likewise restricted to the
vascular endothelium of veins and arterioles but not noted
in the microvasculature (Fig. 4C). In pancreas, the expres-
sion was also detected only in the vascular endothelial
cells and vascular smooth muscle cells (Fig. 4D and I). In
islets of Langerhans of the pancreas, the -, -, and -cells
were all negative for Cd39/Entpd1. However, the micro-
vasculature endothelial cells did stain for Cd39/Entpd1 in
the pancreatic tissues and islets. Both wild-type and
Cd39/Entpd1
/ islets stained for glucagon in a compara-
ble manner (Fig. 4K and O); Cd39/Entpd1
/ islets reacted
strongly for insulin (Fig. 4L and P).
Effect of extracellular ATP on glucose metabolism in
hepatocytes. We next analyzed glucose metabolism in
cultured primary hepatocytes isolated from Cd39/Entpd1
/
mice, as hyperinsulinemic-euglycemic clamp studies had
suggested impaired hepatic glucose homeostasis in Cd39/
Entpd1
/ mice. Overall glucose uptakes were signiﬁcantly
decreased in Cd39/Entpd1
/ hepatocytes in vitro (Fig. 5A).
The glucose uptake by wild-type hepatocytes was
signiﬁcantly decreased in the presence of ATP (Fig. 5B).
Major contributions of liver to systemic glucose ho-
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FIG. 3. Cd39/Entpd1
/ mice manifest impaired hepatic glucose homeostasis during hyperinsulinemic-euglycemic clamp. A: Tissue glucose uptake
estimated by 2-DG. B: Glucose infusion rate. C: Glucose disappearance rate (Rd). A–C: f, Cd39/Entpd1
/ mice; , wild-type (WT) mice. D:
Hepatic glucose production and its suppression by insulin. f, Cd39/Entpd1
/ mice ; , wild-type (WT) mice; s, with insulin (n  6 for wild-type
and n  7 for Cd39/Entpd1
/ mice); solid bars, basal. Data are means  SE. **P < 0.05.
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is suppressed by insulin. Glucose production was much
higher in Cd39/Entpd1
/ hepatocytes than the wild-
type hepatocytes. The increased level of glucose pro-
duction by Cd39/Entpd1
/ hepatocytes was not
signiﬁcantly suppressed by insulin. In contrast, wild-
type hepatocytes had the expected statistically signiﬁ-
cant suppression by insulin with respect to the glucose
production (Fig. 5C). Exogenous extracellular ATP also
induced higher levels of glucose production in wild-type
hepatocytes; this was not suppressed by insulin (Fig.
5D).
Susceptibility of c-JNK phosphorylation by exoge-
nous ATP treatment. c-JNK is a member of mitogen-
activated protein kinase family that is activated by various
proinﬂammatory cytokines. The activated c-JNK phos-
phorylates serine residues of IRS-1/2 and consequently
prevents tyrosine phosphorylation of IRS-1/2 by insulin
receptor (16). As extracellular ATP treatment induces
c-JNK activation in rat hepatocytes (14), we examined
phosphorylation levels of c-JNK in mouse liver after portal
venous administration of ATP in vivo. We noted that
phosphorylation of c-JNK in Cd39/Entpd1
/ mice liver at
30 min after ATP administration was signiﬁcantly higher
than in wild-type mice (Fig. 6A).
Decreased tyrosine phosphorylation of hepatic IRS-2
in Cd39/Entpd1
/ mice. Tyrosine phosphorylation of
IRS could be hampered by phosphorylation of adjacent
serine residues of IRS mediated by inﬂammatory kinase
such as c-JNK or protein kinase C (16,17). Such kinases
are activated through the activation of purinergic recep-
tors by extracellular ATP (14,15). We therefore examined
phosphorylation of IRS-1 and -2 in wild-type and Cd39/
Entpd1
/ mice liver to dissect out differential responses
to insulin in vivo. There were no differences in levels of
tyrosine phosphorylation of IRS-1 between wild-type and
Cd39/Entpd1
/ mice liver samples after insulin adminis-
tration (Fig. 7). However, tyrosine phosphorylation of
IRS-2 was markedly suppressed in Cd39/Entpd1
/ murine
liver relative to wild-type samples postinjection of insulin.
Relative levels of hepatic Ser-731 phosphorylation of IRS-2
were higher in Cd39/Entpd1
/ mice when compared with
wild-type mice tissues (Fig. 7D).
Serum proinﬂammatory cytokine levels. Increased lev-
els of proinﬂammatory cytokines are known to induce
insulin resistance by activating kinases such as c-JNK.
Extracellular nucleotides also clearly activate inﬂamma-
tory pathways. Therefore, we have measured the serum
levels of proinﬂammatory cytokines as surrogates for
basal inﬂammatory responses in Cd39/Entpd1
/ mice.
liver muscle BAT pancreas
Cd39/Entpd1 Cd31 glucagon insulin
Tissues
Pancreatic
Islets
ABCD
EFGH
IJ K L
MNOP
Cd39/Entpd1
Cd31
Cd39/Entpd1-/-
Wt
(+/+) (-/-)
FIG. 4. Immunohistochemical analysis. Various insulin-sensitive tissues together with pancreatic islets were analyzed for Cd39 expression and
are compared with the vascular endothelial marker Cd31. In the lower right panels, islet content of glucagon and insulin are also displayed. A–D,
I, and M: Expression of Cd39/Entpd1. E–H, J, and N: Stained for Cd31. A and E: From wild-type liver. B and F: Wild-type skeletal muscle. C and
G: Wild-type brown adipose tissue (BAT). C: Inserted microimage, at large magniﬁcation. (
/), wild-type BAT. (
/), Cd39/Entpd1-null BAT
serves as a negative control. D and H: Wild-type pancreas. I and J are islet tissues from wild-type mice, whereas M and N are from the
Cd39/Entpd1-null mice. K (wild type) and O (null) are stained for glucagon. L (wild type) and P (null) show the staining patterns for insulin (see
text for details). (Please see http://dx.doi.org/10.2337/db07-1265 for a high-quality digital representation of this ﬁgure.)
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crosis factor- levels are signiﬁcantly higher in Cd39/
Entpd1
/ mice than in wild-type mice (Table 1).
NFBp65 levels were also higher in the Cd39/Entpd1
/
mice liver treated with exogenous ATP (Cd39/Entpd1
/
mice 178.5  24.1 vs. wild-type mice 100.0  9.5 [arbitrary
units]; P  0.0019).
DISCUSSION
We have shown that deletion of Cd39/Entpd1 results in
abnormalities of glucose homeostasis and causes insulin
resistance. We show that the plasma insulin levels are
higher in Cd39/Entpd1
/ mice than in wild-type mice
during a GTT, and islets stain strongly for insulin in
Cd39/Entpd1
/ mice tissues. Glucose intolerance in
Cd39/Entpd1
/ mice does not appear to be related to an
intrinsic abnormality in insulin secretion from -cells.
Signiﬁcant effects of ATP administration on the GTT in
contrast to other nucleotides suggest involvement of P2X
receptors that are uniquely activated by ATP in the expres-
sion of glucose intolerance.
Cd39/Entpd1
/ mice are not obese, but leptin levels are
increased. Leptin is an important anorexigenic hormone
secreted from adipocytes (24–26). Insulin may induce
secretion of leptin (27). Therefore, it is possible that the
hyperinsulinemia of Cd39/Entpd1
/ mice might be a
cause for hyperleptinemia. The food intake of Cd39/
Entpd1
/ mice was comparable with those of wild-type
mice despite the increased levels of plasma leptin. Leptin
is also known to increase energy expenditure. However,
calorimetric analysis of Cd39/Entpd1
/ mice revealed
decreased heat generation and energy consumption both
during dark and light cycles. Respiratory ratios of Cd39/
Entpd1
/ mice were slightly lower than wild-type mice.
Potentially, other tissue-speciﬁc mechanisms might exist
for the regulation of energy consumption by extracellular
B
D
A
C
FIG. 5. Effect of extracellular ATP on glucose metabolism in hepatocytes. A: 2-DG uptake by Cd39/Entpd1
/ mice and wild-type (WT) mice
hepatocytes. B: Effect of extracellular ATP on 2-DG uptake by wild-type mice hepatocytes. C: Hepatic glucose production of Cd39/Entpd1
/ mice
and wild-type (WT) mice hepatocytes and its suppression by insulin. D: Effect of extracellular ATP on glucose production in wild-type
hepatocytes. Experiment was performed in triplicate. A and C: f, Cd39/Entpd1
/ mice; , wild-type mice. B and D: , without ATP; f, with ATP.
**P < 0.05; *P > 0.05 by ANOVA but P < 0.05 by Student’s t test.
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sibility of both leptin resistance as well as insulin resis-
tance in Cd39/Entpd1
/ mice.
Hyperinsulinemic-euglycemic clamp studies identiﬁed
the liver as a major target organ for the effects of Cd39/
Entpd1 on glucose homeostasis and insulin resistance.
Immunohistochemical studies showing Cd39/Entpd1 to be
expressed dominantly within the vasculature suggest that
observed insulin resistance are secondary to modulation
of extracellular and plasma nucleotides levels brought by
loss of vascular ecto-nucleotidase activity. This is different
mechanistically from the type of insulin resistance in-
duced by a K121Q variant of PC-1 (ectonucleotide pyro-
phosphatase/phosphodiesterase). The latter requires direct/
physical interactions between insulin receptor and PC-1
(28,29). Furthermore, PC-1 is expressed in skeletal muscle
cells and hepatocytes unlike the unique vascular expres-
sion of Cd39/Entpd1.
We next examined aspects of glucose metabolism in
primary hepatocyte cultures of Cd39/Entpd1
/ and wild-
type mice. In general, glucose transport by hepatocytes is
insulin-independent. However, expression of glucokinase
is induced by insulin. We noted that the overall uptake of
glucose was signiﬁcantly decreased in Cd39/Entpd1
/
mice hepatocytes. Glucose uptake by wild-type primary
culture hepatocyte was also signiﬁcantly decreased by
treatment with extracellular ATP, albeit not to the same
extent as with Cd39/Entpd1
/ hepatocytes. ATP is known
to induce hepatic gluconeogenesis (30) and impact upon
glucose release via P2X4 receptor–mediated increases in
glycogenolysis (31). Our and these published data suggest
that the cellular phenotype seen in the Cd39/Entpd1
/
mice may be directly dependent upon exposure to extra-
cellular nucleotides. We suggest that these are differential
and persistent purinergic responses in these target tissues
that are impacted upon by loss of Cd39/Entpd1 in vascu-
lature. We infer that the reduced Rd values observed in
Cd39/Entp1
/ mice during the hyperinsulinemic-euglyce-
mic studies are secondary due, in substantial part, to the
decreased glucose uptake in hepatocytes.
Other contributions of insulin to hepatic glucose ho-
meostasis include the suppression of glucose production.
Liver-speciﬁc insulin receptor knockout mice exhibit he-
patic insulin resistance (i.e., impaired insulin-mediated
suppression of hepatic glucose production that is accom-
panied by elevated plasma insulin levels). These features
are also observed in Cd39/Entpd1
/ mice, suggesting
indirect effects on insulin receptor activity (32).
Cd39/Entpd1
/ mice hepatocytes also show signiﬁcantly
higher basal glucose production than that seen in wild-type
mice hepatocytes. Furthermore, the glucose production of
Cd39/Entpd1
/ mice hepatocytes is not suppressed by the
treatment of insulin, unlike in the instance of wild-type mice
hepatocytes, in which this is suppressed by insulin. Interest-
ingly, ATP treatment of wild-type hepatocytes also induces
heightened hepatic glucose production, even in the presence
of insulin. These results conﬁrm that extracellular ATP
regulates glucose homeostasis in hepatocytes. Further-
more, Cd39/Entpd1 expressed on adjacent cells, such as
endothelial cells, is likely to regulate insulin signals in the
hepatocyte by modulating extracellular nucleotide levels
in the immediate microenvironment in vivo. It is worthy of
mention that vascular endothelial-speciﬁc insulin receptor
knockout mice do not exhibit insulin resistance (33). We
propose that insulin resistance observed in Cd39/En-
tpd1
/ mice is not directly caused by modulation of
vasculature functions but involves other factors (e.g.,
paracrine ﬂuxes of extracellular nucleotides that impact
target tissues such as the hepatocyte).
Activation of cellular signaling cascades by proinﬂam-
matory cytokines such as tumor necrosis factor- and
interleukin-1, free fatty acids, or nucleotides (14) can also
induce cellular activation via inﬂammatory kinases. Acti-
vation of inﬂammatory kinases, such as c-JNK, also cause
aberrant serine phosphorylation of IRS. This speciﬁc form
of serine phosphorylation prevents consequent tyrosine
phosphorylation by insulin receptors and association of
phosphoinositide 3-kinases, leading to impaired insulin
signal transduction (34,35).
To analyze the molecular mechanisms for insulin resis-
tance of Cd39/Entpd1
/ mice, we analyzed tyrosine phos-
phorylation of IRS-1 and -2. Insulin-stimulated tyrosine
phosphorylation of IRS-2 was signiﬁcantly decreased in
Cd39/Entpd1
/ mice liver. In addition, phosphorylation
of c-JNK induced by administration of ATP was also
signiﬁcantly increased in Cd39/Entpd1
/ mice liver.
These data suggest that insulin resistance of Cd39/
Entpd1
/ mice is associated with increased activation of
hepatic c-JNK/SAP by extracellular ATP. This likely results
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FIG. 6. c-JNK phosphorylation in murine liver. Mice were administered
ATP via portal vein and the liver was harvested at 30 min after
injection. The lysates were analyzed by Western blotting with anti–
phospho-JNK antibodies or anti-JNK antibodies. A: Quantiﬁcation of
p-JNK to total JNK ratio by Western blot analysis. , wild-type (WT)
mice; f, Cd39/Entpd1
/; s, ATP-treated mice (n  3); solid bars,
saline control mice. B: Representative staining of Western blot for
p-JNK and JNK. P, a positive control. C: Quantiﬁcation of NFBp65 in
murine liver nuclear extracts (n  8–9). f, wild-type (WT) mice; ,
Cd39/Entpd1
/ mice. **P < 0.05; *P > 0.05 by ANOVA but P < 0.05 by
Student’s t test.
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creased tyrosine phosphorylation of IRS-2. Similar pat-
terns of aberrant IRS-2 phosphorylation have been noted
in other insulin resistance states (36).
Furthermore, several features observed in Cd39/
Entpd1
/ mice are also seen in IRS-2
/ mice: both
show elevated plasma insulin levels and have normal
fasting blood glucose levels with impaired glucose ho-
meostasis in the liver. IRS-2
/ mice, however, show
increases in blood glucose levels with advancing age
due to lack of compensatory -cell hyperplasia (37).
Other cellular candidates for mediating insulin resis-
tance of Cd39/Entpd1
/ mice include immune cells such
as macrophages in adipose tissues and the Kupffer cells of
the liver, as alluded to above (35). Activation of purinergic
signaling pathways is already known to induce secretion of
cytokines from both immune and endothelial cells (38–42).
We show that serum proinﬂammatory cytokine levels (inter-
leukin-1, interleukin-6, interferon-, and tumor necrosis
factor-) are signiﬁcantly higher in Cd39/Entpd1
/ mice
than in wild-type mice. Accordingly, hypersecretion of select
cytokines by monocytes and other cells also might contrib-
ute, at least in part, to the development of insulin resistance
in Cd39/Entpd1
/ mice.
Our data suggest that insulin resistance in Cd39/
NTPDase1
/ mice is associated with disordered extracel-
lular nucleotide signaling that directly impacts important
metabolic pathways in hepatocytes via aberrant IRS-2
phosphorylation. However, we do not exclude the possi-
bility that deletion of Cd39 might also contribute to insulin
resistance in a somewhat more indirect manner via the
induction of inﬂammatory cytokines. The relative contri-
butions of these two nonexclusive mechanisms remain to
be determined.
We have already reported on other vascular and immune
abnormalities in Cd39/Entpd1
/ mice. This described
phenotype includes disordered thromboregulation, aber-
rant inﬂammatory responses, impaired angiogenesis and
regeneration of the liver, impaired function of regulatory
T-cells, and predisposition to diabetic renal diseases with
increased proteinuria and hypertension (3,5,12,15,42). To
these manifestations of Cd39/Entpd1 deletion, we now add
metabolic consequences.
In conclusion, Cd39/Entpd1 expressed by the vascula-
ture and by immune cells serves as an important modula-
tor of hepatic carbohydrate metabolism. The pathogenetic
mechanism involves failure to control extracellular nucle-
FIG. 7. Impaired tyrosine phosphorylation of IRS-2 in Cd39/Entpd1
/
liver. Age-matched 12- to 15-week-old male mice were starved for 16 h
(1700–1000h) then received human regular insulin at 5 units/kg body
wt i.v., and the tissues were collected at 5 min after injection. Lysates
were immunoprecipitated with anti-IRS antibodies and protein A/G
Sepharose and then probed with anti-tyrosine antibodies. A: Quantiﬁ-
cation of p–IRS-1/2 to total IRS-1/2 by Western blot analysis. ,
wild-type (WT) mice; f, Cd39/Entpd1
/ mice; s, insulin-treated mice;
solid bars, saline treated (n  3). **P < 0.05. B: Representative
staining of Western blot for p–IRS-1/2 or total IRS-1/2. C: Quantiﬁca-
tion of p–Ser731–IRS-2 to total IRS-2 by Western blot analysis (n  3).
**P < 0.05. D: Representative staining of Western blot for p–Ser731–
IRS-2 or total IRS-2.
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